Epidemiological marker for oxidant status: Comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15- F 2t-isoprostane

Annals of Epidemiology

Volumn 14, Issue 10, 2004, Pages 793-797

  Il'yasova, Dora ^a,b   Morrow, Jason D ^a   Ivanova, Anastasia ^a   Wagenknecht, Lynne E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Epidemiology; Isoprostanes; Oxidative Stress

Indexed keywords

2,3 DINOR 5,6 DIHYDRO 15 F2T ISOPROSTANE; 8 ISOPROSTAGLANDIN F2 ALPHA; BIOLOGICAL MARKER; CREATININE; ISOPROSTANE DERIVATIVE; OXIDIZING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID OXIDATION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LINEAR SYSTEM; MALE; MASS SPECTROMETRY; METABOLITE; PRIORITY JOURNAL; STATISTICS; URINE; VALIDATION PROCESS;

ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGIC METHODS; F2-ISOPROSTANES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; OBESITY;

EID: 7444250830     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2004.03.003     Document Type: Article

References (24)

1. G. Block, M. Dietrich, E.P. Norkus, J.D. Morrow, M. Hudes, and B. Caan Factors associated with oxidative stress in human populations Am J Epidemiol 156 2002 274 285
2. B. Halliwell Lipid peroxidation, antioxidants and cardiovascular disease: How should we move forward? Cardiovasc Res 47 2000 410 418
3. B. Halliwell The antioxidant paradox Lancet 355 2000 1179 1180
4. D. Steinberg, and J.L. Witztum Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105 2002 2107 2111
5. L.J. Roberts, and J.D. Morrow Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo Free Radic Biol Med 28 2000 505 513
6. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J. Roberts A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc Natl Acad Sci USA 87 1990 9383 9387
7. M. Richelle, M.E. Turini, R. Guidoux, I. Tavazzi, S. Metairon, and L.B. Fay Urinary isoprostane excretion is not confounded by the lipid content of the diet FEBS Lett 459 1999 259 262
8. S. Devaraj, S.V. Hirany, R.F. Burk, and I. Jialal Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes Clin Chem 47 2001 1974 1979
9. J. Helmersson, and S.F. Basu 2-isoprostane excretion rate and diurnal variation in human urine Prostaglandins Leukot Essent Fatty Acids 61 1999 203 205
10. Z. Wang, G. Ciabattoni, C. Creminon, J. Lawson, G.A. FitzGerald, and C. Patrono Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man J Pharmacol Exp Ther 275 1995 94 100
11. E.A. Meagher, O.P. Barry, J.A. Lawson, J. Rokach, and G.A. FitzGerald Effects of vitamin E on lipid peroxidation in healthy persons JAMA 285 2001 1178 1182
12. T. Ide, H. Tsutsui, N. Ohashi, S. Hayashidani, N. Suematsu, and M. Tsuchihashi Greater oxidative stress in healthy young men compared with premenopausal women Arterioscler Thromb Vasc Biol 22 2002 438 442
13. J.D. Morrow, W.E. Zackert, J.P. Yang, E.H. Kurhts, D. Callewaert, and R. Dworski Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay Anal Biochem 269 1999 326 331
14. 2t Isoprostane by colorimetric and chemiluminescence ELISAS. Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, 7th International Conference, October 14-17, 2001, Nashville, TN. 2001;170:159.
15. D.M. Sasaki, Y. Yuan, K. Gikas, K. Kanai, D. Taber, and J.D. Morrow Enzyme immunoassays for 15-F2T isoprostane-M, an urinary biomarker for oxidant stress Adv Exp Med Biol 507 2002 537 541
16. L.E. Wagenknecht, E.J. Mayer, M. Rewers, S. Haffner, J. Selby, and G.M. Borok The Insulin Resistance Atherosclerosis Study (IRAS) objectives, design, and recruitment results Ann Epidemiol 5 1995 464 472
17. M.H. Kroll, R. Chesler, C. Hagengruber, D.W. Blank, J. Kestner, and M. Rawe Automated determination of urinary creatinine without sample dilution: Theory and practice Clin Chem 32 1986 446 452
18. C.R. Morales, E.S. Terry, W.E. Zackert, T.J. Montine, and J.D. Morrow Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay Clin Chim Acta 314 2001 93 99
19. B. Halliwell Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 344 1994 721 724
20. B. Halliwell, and J.M.C. Gutteridge Free Radicals in Biology and Medicine 1999 Oxford University Press Oxford
21. J.D. Morrow, and L.J. Roberts The isoprostanes: Their role as an index of oxidant stress status in human pulmonary disease Am J Respir Crit Care Med 166 2002 S25 S30
22. L.J. Roberts Comparative metabolism and fate of ecosanoids A.L. Willis CRC Handbook of Eicosanoids Prostaglandins and Related Lipids 1987 CRC Press Boca Raton, FL 239 244
23. J. Proudfoot, A. Barden, T.A. Mori, V. Burke, K.D. Croft, and L.J. Beilin Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry Anal Biochem 272 1999 209 215
24. J. Bessard, J.L. Cracowski, F. Stanke-Labesque, and G. Bessard Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay J Chromatogr B Biomed Sci Appl 754 2001 333 343